Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
22. August 2024 16:30 ET
|
Travere Therapeutics, Inc.
Travere today announced that it will present two posters in classical homocystinuria (HCU) at the SSIEM annual symposium.
Travere Therapeutics to Present at Upcoming Investor Conferences
06. August 2024 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August:...
Travere Therapeutics Reports Second Quarter 2024 Financial Results
01. August 2024 16:01 ET
|
Travere Therapeutics, Inc.
Received 521 new patient start forms (PSFs) for FILSPARI® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch Net product...
Travere Therapeutics to Report Second Quarter 2024 Financial Results
25. Juli 2024 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced it will report second quarter 2024 financial results on Thursday, August 1, 2024, after the...
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
08. Juli 2024 16:30 ET
|
Travere Therapeutics, Inc.
Travere Therapeutics management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m. ET.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11. Juni 2024 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15. Mai 2024 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement...
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
09. Mai 2024 16:30 ET
|
Travere Therapeutics, Inc.
Presentations highlight data supporting FILSPARI® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN SAN DIEGO, May 09, 2024 ...
Travere Therapeutics to Present at Upcoming Investor Conferences
08. Mai 2024 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA...
Travere Therapeutics Reports First Quarter 2024 Financial Results
06. Mai 2024 16:01 ET
|
Travere Therapeutics, Inc.
FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 ...